West Coast Retina Medical Group - San Francisco

West Coast Retina Medical Group Inc.

Macular Degeneration

Wet Macular Degeneration

Geographic Atrophy

Atrophy

IONIS-FB-LRx

Ranibizumab

Ionis Pharmaceuticals

Roche

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.

Extension Study for the Port Delivery System With Ranibizumab (Portal)

West Coast Retina Medical Group Inc. | West Coast Retina Medical Group - San Francisco

Site insights

Work at this site?

Active trials

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Trial sponsors